Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.

ABSTRACT:

Purpose

The ATM (ataxia telangiectasia mutated) gene is mutated in a subset of prostate cancers, and ATM mutation may confer specific therapeutic vulnerabilities, although ATM-deficient prostate cancers have not been well-characterized.

Experimental design

We genetically validated a clinical grade IHC assay to detect ATM protein loss and examined the frequency of ATM loss among tumors with pathogenic germline ATM mutations and genetically unselected primary prostate carcinomas using tissue microarrays (TMAs). Immunostaining results were correlated with targeted somatic genomic sequencing and clinical outcomes.

Results

ATM protein loss was found in 13% (7/52) of primary Gleason pattern 5 cancers with available sequencing data and was 100% sensitive

SUBMITTER: Kaur H 

PROVIDER: S-EPMC7501149 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature